Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017482 · ClinicalTrials.gov registry record
Clinical Startup of the 670G Closed Loop Insulin Delivery System
A clinical trial of Diabetes Mellitus, Type 1, sponsored by Stanford University.
- Completed
- Registry status
- 85
- Enrollment target
- 1
- Study location
NCT03017482: Completed study of Diabetes Mellitus, Type 1, sponsored by Stanford University.
NCT03017482 is a study of Diabetes Mellitus, Type 1 that has completed, run by Stanford University. The registered enrollment target is 85 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03017482, a study of Diabetes Mellitus, Type 1, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to track initiation and the first year of clinical use of the newly FDA approved 670G closed loop insulin delivery system by patients who have requested this system. Our goal is to evaluate our clinical approach to starting this newly approved system. Since the investigators are only following patients who have already decided to start the 670G, the investigator does not assign specific interventions to the subjects of the study; thus this is a Observational study.
Primary Outcome
percent of time patients are on the closed loop system at 6 months after start of closed loop activation with a goal of \>70%.
Conditions Studied
Interventions
- DEVICE Medtronic 670G
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2019-08-30 |
What the finished NCT03017482 record still lists
NCT03017482 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Medtronic 670G is the first listed.
NCT03017482 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03017482 about?
NCT03017482 is a clinical study titled "Clinical Startup of the 670G Closed Loop Insulin Delivery System". The purpose of this project is to track initiation and the first year of clinical use of the newly FDA approved 670G closed loop insulin delivery system by patients who have requested this system. Our goal is to evaluate our clinical approach to starting this newly approved system. Since the investi...
What is the current status of trial NCT03017482?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-07-15. Estimated completion is 2019-08-30.
What conditions does trial NCT03017482 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03017482?
The interventions under investigation include: Medtronic 670G (DEVICE).
Who is sponsoring clinical trial NCT03017482?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03017482 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03017482's enrollment target sits among peer trials
85 51st of 118 higher than 68 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI